Ocugen (OCGN)

Executive Summary

Ocugen is a clinical-stage biotechnology company developing a novel modifier gene therapy platform for inherited retinal diseases. Its lead candidate, OCU400, is in Phase 3 for retinitis pigmentosa and has the potential to be a first-in-class, gene-agnostic treatment. The company also has OCU410ST in Phase 2/3 for Stargardt disease and OCU200 in Phase 1 for diabetic macular edema. Despite a setback with its COVID-19 vaccine, Ocugen's robust pipeline targeting significant unmet needs in ophthalmology positions it for potential value creation. Key upcoming milestones include data readouts from its late-stage trials, which could drive near-term stock performance. However, the company remains a high-risk investment given the early stage of most programs and inherent R&D risks.

Upcoming Catalysts (preview)

• Q3 2026OCU400 Phase 3 interim analysis for retinitis pigmentosa60% success
• Q4 2026OCU410ST Phase 2/3 top-line data for Stargardt disease55% success
• Q3 2026OCU200 Phase 1 safety/efficacy data for diabetic macular edema45% success